Benzinga's Top Upgrades, Downgrades For May 2, 2018

Top Upgrades

  • Mizuho upgraded Ironwood Pharmaceuticals, Inc. IRWD from Neutral to Buy. Ironwood Pharmaceuticals shares rose 2.09 percent to $19.08 in pre-market trading.
  • Wedbush upgraded TCF Financial Corporation TCF from Underperform to Neutral. TCF Financial shares rose 1.33 percent to close at $25.16 on Tuesday.
  • Raymond James upgraded United States Cellular Corporation USM from Market Perform to Outperform. United States Cellular shares fell 14.03 percent to close at $34.02 on Monday.
  • Analysts at Deutsche Bank upgraded Juniper Networks, Inc. JNPR from Sell to Hold. Juniper shares rose 6.87 percent to $26.45 in pre-market trading.
  • Bank of America upgraded Vulcan Materials Company VMC from Neutral to Buy. Vulcan Materials shares rose 0.07 percent to close at $111.77 on Tuesday.
  • DA Davidson upgraded Domtar Corporation UFS from Underperform to Neutral. Domtar shares rose 2.67 percent to close at $45.07 on Monday.
  • Bank of America upgraded Eaton Vance Corp. EV from Neutral to Buy. Eaton Vance shares fell 1.08 percent to close at $53.80 on Monday.
  • CIBC upgraded Freeport-McMoRan Inc. FCX from Neutral to Outperformer. Freeport-McMoRan shares rose 2.08 percent to $15.23 in pre-market trading.
  • Monness Crespi Hardt upgraded Archer-Daniels-Midland Company ADM from Sell to Neutral. Archer-Daniels Midland shares rose 0.47 percent to $45.24 in pre-market trading.
  • Goldman Sachs upgraded Shutterfly, Inc. SFLY from Sell to Neutral. Shutterfly shares rose 10.97 percent to $90.50 in pre-market trading.


Top Downgrades

  • Oppenheimer downgraded Snap Inc. SNAP from Outperform to Perform. Snap shares fell 19.84 percent to $11.33 in pre-market trading.
  • Loop Capital downgraded Ulta Beauty, Inc. ULTA from Buy to Hold. Ulta Beauty shares fell 0.65 percent to $249.00 in pre-market trading.
  • Buckingham downgraded Cummins Inc. CMI from Buy to Neutral. Cummins shares fell 2.79 percent to $149.00 in pre-market trading.
  • Longbow Research downgraded Denny's Corporation DENN from Buy to Neutral. Denny's shares dropped 3.65 percent to $16.65 in pre-market trading.
  • UBS downgraded PACCAR Inc PCAR from Buy to Neutral. PACCAR shares fell 0.14 percent to close at $63.58 on Monday.
  • Craig-Hallum downgraded Seagate Technology plc STX from Buy to Hold. Seagate shares fell 2.23 percent to $53.00 in pre-market trading.
  • Analysts at SunTrust Robinson Humphrey downgraded KLX Inc. KLXI from Buy to Hold. KLX shares fell 8.6 percent to close at $62.25 on Tuesday.
  • BMO Capital downgraded NuVasive, Inc. NUVA from Outperform to Market Perform. NuVasive shares fell 3.82 percent to $51.11 in pre-market trading.
  • Argus downgraded Hershey Company HSY from Buy to Hold. Hershey shares fell 0.67 percent to close at $91.32 on Monday.
  • Bank of America downgraded The Scotts Miracle Gro SMG from Buy to Underperform. Intevac shares fell 22.90 percent to $5.05 in pre-market trading.


Top Initiations

  • Analysts at B. Riley FBR initiated coverage on Mallinckrodt Public Limited Company MNK with a Neutral rating. The price target for Mallinckrodt is set to $15. Mallinckrodt shares closed at $13.10 on Tuesday.
  • Analysts at Jefferies initiated coverage on Sierra Metals Inc. SMTS with a Hold rating. Sierra Metals shares closed at $2.76 on Tuesday.
  • H.C. Wainwright initiated coverage on ChemoCentryx, Inc. CCXI with a Buy rating. The price target for ChemoCentryx is set to $20. ChemoCentryx shares closed at $11.00 on Tuesday.
  • UBS initiated coverage on Fortis Inc. FTS with a Buy rating. Fortis shares closed at $33.51 on Tuesday.
  • SunTrust Robinson Humphrey initiated coverage on Spotify Technology S.A. SPOT with a Buy rating. The price target for Spotify Technology is set to $200. Spotify Technology shares closed at $164.88 on Tuesday.
  • Jefferies initiated coverage on Alcoa Corporation AA with a Buy rating. The price target for Alcoa is set to $65. Alcoa shares closed at $51.99 on Tuesday.
  • Janney Capital initiated coverage on Summit Therapeutics plc SMMT with a Buy rating. The price target for Summit Therapeutics is set to $27. Summit Therapeutics shares closed at $13.18 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: UpgradesDowngradesInitiationPre-Market OutlookAnalyst RatingsInitiationstop upgrades
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!